Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia

Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents

(2019) M.L. Rizk et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial

(2019) Marin H Kollef et al.   LANCET INFECTIOUS DISEASES

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects

(2018) Matthew L. Rizk et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Culture-Negative Septic Shock Compared With Culture-Positive Septic Shock

(2018) Shravan Kethireddy et al.   CRITICAL CARE MEDICINE

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013–2015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program

(2018) Dee Shortridge et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Renal Dosing of Antibiotics: Are We Jumping the Gun?

(2018) Ryan L Crass et al.   CLINICAL INFECTIOUS DISEASES

Microbial cause of ICU-acquired pneumonia

(2018) Charles-Edouard Luyt et al.   Current Opinion in Critical Care

Is One Sample Enough? β-lactam Target Attainment and Penetration into Epithelial Lining Fluid based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model

(2018) Ana Motos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

(2018) George H Talbot et al.   JOURNAL OF INFECTIOUS DISEASES

Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art

(2017) Alberto Enrico Maraolo et al.   Expert Review of Anti-Infective Therapy

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016

(2017) Andrew Rhodes et al.   INTENSIVE CARE MEDICINE

Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L

(2017) Senthil Natesan et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects

(2016) Todd A. Riccobene et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

(2016) Andre C. Kalil et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects

(2016) Anthony Aiudi et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae

(2016) Elizabeth A. Neuner et al.   Virulence

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections

(2016) Kellie Goodlet et al.   Therapeutics and Clinical Risk Management

Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects

(2015) Eric Wenzler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pseudomonas aeruginosa Nosocomial Pneumonia: Impact of Pneumonia Classification

(2015) Scott T. Micek et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens

(2015) David P. Nicolau et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia

(2015) Alan J. Xiao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The effect of pathophysiology on pharmacokinetics in the critically ill patient — Concepts appraised by the example of antimicrobial agents

(2014) Stijn I. Blot et al.   ADVANCED DRUG DELIVERY REVIEWS

Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam

(2014) Myra Wooley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Empiric Antibiotic Treatment Reduces Mortality in Severe Sepsis and Septic Shock From the First Hour

(2014) Ricard Ferrer et al.   CRITICAL CARE MEDICINE

Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections

(2014) Gurudatt Chandorkar et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

(2014) Jason A Roberts et al.   LANCET INFECTIOUS DISEASES

Life-Threatening Infections in the Critically Ill

(2013) Anand Kumar   CRITICAL CARE CLINICS

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009–2011)

(2013) Helio S. Sader et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli

(2013) George G. Zhanel et al.   DRUGS

In VivoActivities of Ceftolozane, a New Cephalosporin, with and without Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, Including Strains with Extended-Spectrum β-Lactamases, in the Thighs of Neutropenic Mice

(2012) W. A. Craig et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Safety of Intravenous Ceftolozane-Tazobactam in Healthy Adult Subjects following Single and Multiple Ascending Doses

(2012) Benjamin Miller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects

(2012) G. Chandorkar et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid

(2011) Keith A. Rodvold et al.   CLINICAL PHARMACOKINETICS

Initiation of Inappropriate Antimicrobial Therapy Results in a Fivefold Reduction of Survival in Human Septic Shock

(2009) Anand Kumar et al.   CHEST